Perfluoropolyether Spray Reduces Cavitation Bubbles in Light Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current light therapy treatments for skin conditions, such as tattoo removal, face challenges due to 'whitening reactions' caused by gas bubble formation, which reduce treatment effectiveness and require lengthy sessions as bubbles take time to resolve, and existing methods using perfluorodecalin are impractical and inefficient.
Innovation Solution
The use of a perfluoropolyether topically applied before light therapy reduces gas bubble formation, allowing for faster resolution of whitening reactions, increased effectiveness of each light pass, and reduced number of treatment sessions, while forming a transparent film for efficient light delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If perfluorodecalin is applied using a patch soaked with the chemical facilitator, then the whitening reaction can be resolved, but the effective amount of the chemical facilitator cannot be dosed and the physical features of the patch can hinder the resolution of the whitening reaction
Solution Approach 1:
The patent changes the physical state and formulation parameters by using a sprayable composition instead of a soaked patch, allowing for precise dosing control through spray application while maintaining the therapeutic effect of resolving whitening reactions
Solution Approach 2:
The patent introduces a sprayable composition as an intermediary carrier that delivers the perfluorodecalin chemical facilitator directly to the treatment area without the interfering physical features of a soaked patch, enabling both effective dosing and unhindered resolution of whitening
2Reliability
If a patch soaked with perfluorodecalin is used, then the whitening reaction can be addressed, but the patch does not cover the whole skin surface to be treated and the physician has to move the patch during the light therapy
Solution Approach 1:
The sprayable composition provides universal coverage capability, allowing the entire skin surface to be treated uniformly in a single application without requiring multiple patches or movement during the light therapy procedure
Solution Approach 2:
The patent extracts the perfluorodecalin from the patch medium and formulates it as a standalone sprayable composition, eliminating the limitations of patch-based delivery and enabling complete skin surface coverage
3Object-affected harmful factors
If clinicians wait for the spontaneous resolution of bubbles, then the adverse consequences of whitening can be avoided, but lengthy treatment times are required and multiple treatment sessions are needed
Solution Approach 1:
The sprayable composition is applied preliminarily before light therapy to prevent bubble formation and whitening reactions from occurring in the first place, eliminating the need to wait for spontaneous resolution and reducing treatment time
Solution Approach 2:
The perfluorodecalin in the sprayable composition acts preliminarily to counteract the bubble formation mechanism that causes whitening reactions, preventing the harmful effect before it occurs rather than waiting for it to resolve
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Perfluoropolyether significantly shortens the time for resolving whitening reactions, enhances the effectiveness of each light therapy session, reduces adverse effects like burning and scarring, and decreases the number of sessions needed for treatments like tattoo removal, improving skin healing and overall treatment efficiency.
Implementation Method 1
the laser induces immediate whitening reactions that are hypothesized to result from thermally induced cavitation bubble formation
Implementation Method 2
forming a transparent film for efficient light delivery
Implementation Method 3
exposing the skin treatment area to one or more light outputs
Data Source
AI summary
The present invention relates to a perfluoropolyether for use in a light therapy treatment of a skin disease, wherein the skin disease is selected from the group consisting of skin dyspigmentation, varicosities, vascular lesions, telangiectasis, and benign pigmented lesions; or alternatively a non- therapeutic use in a light therapy treatment of a skin condition, wherein the skin condition is selected from the group consisting of skin dyspigmentation, benign pigmented lesions and skin with tattoo;wherein the ligth therapy treatment comprises:(a) first applying a topical composition comprising an effective amount of the perfluoropolyether together with one or more topically acceptable excipients or carriers to the skin treatment area; and then(b) exposing the skin treatment area of step (a) to one or more light outputs. It also relates to compositions containing the perfluoropolyether.